One of the most distressing consequences of the climacteric are the vaso motor symptoms known as hot flashes (hot flushes in the UK) and nocturnal sweats. Mere men, can grossly underestimate the impact of these symptoms on the quality of life of countless women, many of whom are at the peak of their professional lives. The physiological mechanisms to explain these symptoms are ill understood, although the recent description of a membrane bound oestrogen receptor on endothelial cells whereby the binding of oestrogen triggers an energy transduction cascade might begin to provide a logical explanation [1] .
Carcinoma of the breast occurs commonly around the time of the climacteric or amongst women currently taking hormone replacement therapy. Furthermore for pre-menopausal women the indirect ovarian suppression induced by cytotoxic chemotherapy can contribute to these symptoms. Thus women with breast cancer might face menopausal symptoms which are occurring naturally or which are induced by the withdrawal of hormone replacement therapy or the induction of ovarian suppression.
The conventional wisdom, is that oestrogen replacement therapy under these circumstances is contra-indicated because of the belief that exogenous oestrogens can lead to a flare up of breast cancer. There are no good empirical data to support this widespread belief. Furthermore there is the paradox that high doses of oestrogen can lead to regression of advanced breast cancer in elderly women and adjuvant tamoxifen can improve survival in pre-menopausal women whose tumours are oestrogen receptor positive, in spite of inducing very high levels of endogenous oestradiol [2] .
For these reasons oestrogens are often given on an ad hoc basis as a shared decision between clinician and patient [3] . Recently a feasibility randomised trial has been completed at the Royal Marsden Hospital, London, and on the basis of this two large scale National trials are in progress in Sweden and in the UK. It will be many years before we have the data that will allow us to make evidence based recommendations on the wisdom or otherwise of oestrogen replacement therapy in breast cancer survivors suffering from the vasomotor symptoms of the menopause allowing for the recruitment and follow-up of these studies.
In the meantime what are we to offer these unfortunate women, particularly in the climate of defensive medicine where many clinicians in the USA would be frightened of prescribing the one specific likely to work. All alternatives to oestrogen that have been advocated are of little if any value. It is therefore with this in mind that I welcome the pilot study for the use of selective serotonin-reputake inhibitors in the treatment of hot flashes for women who are breast cancer survivors. The uncontrolled data are truly encouraging and I strongly endorse the conclusions from the study that a full scale randomised controlled trial is necessary before the treatment can be offered as standard. In the meantime the results of their pilot study are of physiological interest and it is just possible that their observations might have a sound biological basis by compensating for the effect of the oestrogen withdrawal on the energy transduction pathways within the endothelial cells of the cutaneous and sub-cutaneous vasculature. Who knows, in the long term this class of drugs might even inhibit the development of Altzheimer's disease.
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